title: [Carbohydrate sweeteners and obesity].
abstract: The U.S. prevalence of obesity increases since the mid-70s of the 20th century. Around that time high-fructose corn syrup (HFCS)--mixture of fructose and glucose was introduced as a sweetener replacing sucrose in the food production. HFCS containing 55% fructose and 42-45% glucose (HFCS55) has dominated the American soft drink industry and HFCS has recently become commonly used in Poland. The coincidence of HFCS introduction and obesity epidemic raised widely publicized suspicions of a causal relationship between the two. As a possible mechanism, a higher content of fructose in the HFCS55, as compared with sucrose was suggested -fructose is known to increase serum uric acid level, induce hepatic lipogenesis and not stimulate postprandial hyperinsulinemia, a main activator of leptin release. Few comparative studies of HFCS and sucrose have largely failed to reveal any different impacts on the metabolic parameters, yet they were mainly short-term. It has been recently shown that obesity is linked with changes in the intenstinal flora. Among the causes of allegedly different effects of sucrose and HFCS on metabolism, their influence on the gut microbiome has not been examined. Some bacterial types do not hydrolyze sucrose which may determine different compositions of gut flora with the use of both sweeteners. Studies involving quantitative analysis of bacterial DNA in the stool, both in animals and in humans, shall shed light on the issue that has recently so much absorbed the U.S. public opinion.
authors.affiliation: Katedra i Klinika Chorób Wewnetrznych, Diabetologii i Nefrologii SaIskiego Uniwersytetu Medycznego w Katowicach. wystrych@gmail.com
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Wystrychowski
authors.forename: Ewa
authors.initials: E
authors.lastname: Zukowska-Szczechowska
authors.forename: Ewa
authors.initials: E
authors.lastname: Obuchowicz
authors.forename: Władysław
authors.initials: W
authors.lastname: Grzeszczak
authors.forename: Antoni
authors.initials: A
authors.lastname: Wystrychowski
mesh_terms: D000818:Animals; D015984:Causality; D005243:Feces / Q000382:microbiology; D005632:Fructose / Q000032:analysis / Q000494:pharmacology*; D005947:Glucose / Q000032:analysis / Q000494:pharmacology*; D006801:Humans; D007422:Intestines / Q000382:microbiology; D050155:Lipogenesis / Q000187:drug effects; D008099:Liver / Q000378:metabolism; D054892:Metagenome / Q000187:drug effects; D009765:Obesity / Q000453:epidemiology* / Q000209:etiology / Q000378:metabolism*; D015995:Prevalence; D013549:Sweetening Agents / Q000009:adverse effects / Q000032:analysis / Q000494:pharmacology*; D014527:Uric Acid / Q000097:blood
chemical_list: D013549:Sweetening Agents; D014527:Uric Acid; D005632:Fructose; D005947:Glucose